Drew Ranieri
Stock Analyst at Morgan Stanley
(1.01)
# 3,179
Out of 4,667 analysts
161
Total ratings
38.57%
Success rate
-19.56%
Average return
Main Sectors:
Stocks Rated by Drew Ranieri
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GMED Globus Medical | Maintains: Equal-Weight | $74 → $83 | $83.59 | -0.71% | 11 | Nov 11, 2024 | |
| SIBN SI-BONE | Maintains: Overweight | $21 → $19 | $12.15 | +56.38% | 15 | Aug 6, 2024 | |
| IART Integra LifeSciences Holdings | Maintains: Underweight | $24 → $27 | $22.93 | +17.75% | 15 | Jul 15, 2024 | |
| TMCI Treace Medical Concepts | Maintains: Equal-Weight | $5.5 → $8 | $7.98 | +0.25% | 12 | Jul 15, 2024 | |
| SYK Stryker | Maintains: Equal-Weight | $345 → $350 | $385.68 | -9.25% | 8 | Jul 15, 2024 | |
| STVN Stevanato Group | Maintains: Equal-Weight | $26 → $22 | $18.27 | +20.42% | 16 | Jul 15, 2024 | |
| NPCE NeuroPace | Maintains: Equal-Weight | $9.5 → $8 | $9.19 | -12.95% | 13 | Jul 15, 2024 | |
| ATEC Alphatec Holdings | Maintains: Overweight | $19 → $16 | $9.93 | +61.13% | 8 | Jul 15, 2024 | |
| OM Outset Medical | Maintains: Equal-Weight | $5 → $5.5 | $0.73 | +657.89% | 10 | Dec 4, 2023 | |
| ORGO Organogenesis Holdings | Maintains: Equal-Weight | $3 → $3.5 | $3.97 | -11.84% | 3 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $38 | $20.37 | +86.55% | 9 | Nov 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $88 → $96 | $84.92 | +13.05% | 10 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $28 → $26 | $17.87 | +45.50% | 8 | May 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $290 → $295 | $222.39 | +32.65% | 2 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $236 → $280 | $187.43 | +49.39% | 5 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $5 | $11.41 | -56.18% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $72 → $70 | $32.63 | +114.53% | 4 | Oct 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $325 → $300 | $541.82 | -44.63% | 6 | Apr 25, 2022 |
Globus Medical
Nov 11, 2024
Maintains: Equal-Weight
Price Target: $74 → $83
Current: $83.59
Upside: -0.71%
SI-BONE
Aug 6, 2024
Maintains: Overweight
Price Target: $21 → $19
Current: $12.15
Upside: +56.38%
Integra LifeSciences Holdings
Jul 15, 2024
Maintains: Underweight
Price Target: $24 → $27
Current: $22.93
Upside: +17.75%
Treace Medical Concepts
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $5.5 → $8
Current: $7.98
Upside: +0.25%
Stryker
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $345 → $350
Current: $385.68
Upside: -9.25%
Stevanato Group
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $26 → $22
Current: $18.27
Upside: +20.42%
NeuroPace
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $9.5 → $8
Current: $9.19
Upside: -12.95%
Alphatec Holdings
Jul 15, 2024
Maintains: Overweight
Price Target: $19 → $16
Current: $9.93
Upside: +61.13%
Outset Medical
Dec 4, 2023
Maintains: Equal-Weight
Price Target: $5 → $5.5
Current: $0.73
Upside: +657.89%
Organogenesis Holdings
Nov 14, 2023
Maintains: Equal-Weight
Price Target: $3 → $3.5
Current: $3.97
Upside: -11.84%
Nov 2, 2023
Maintains: Overweight
Price Target: $42 → $38
Current: $20.37
Upside: +86.55%
May 12, 2023
Maintains: Equal-Weight
Price Target: $88 → $96
Current: $84.92
Upside: +13.05%
May 4, 2023
Maintains: Underweight
Price Target: $28 → $26
Current: $17.87
Upside: +45.50%
Feb 3, 2023
Maintains: Overweight
Price Target: $290 → $295
Current: $222.39
Upside: +32.65%
Jan 6, 2023
Maintains: Equal-Weight
Price Target: $236 → $280
Current: $187.43
Upside: +49.39%
Nov 10, 2022
Maintains: Overweight
Price Target: $11 → $5
Current: $11.41
Upside: -56.18%
Oct 11, 2022
Maintains: Overweight
Price Target: $72 → $70
Current: $32.63
Upside: +114.53%
Apr 25, 2022
Maintains: Equal-Weight
Price Target: $325 → $300
Current: $541.82
Upside: -44.63%